Home/Hedge Fund Intelligence/Iovance Biotherapeutics, Inc.
Nasdaq: IOVAStockForm 13F30 Jun 2026

Hedge funds that hold Iovance Biotherapeutics, Inc. Nasdaq: IOVA

CUSIP 462260100 · who reports it, how much, and how much it matters to them

24 of the 720 hedge fund managers we track reported shares of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) on Form 13F for 30 June 2026. Between them they reported USD 168m. The largest position belongs to Two Sigma Investments, at USD 79m. The manager with the most riding on it is Palo Alto Investors, where it is 3.0% of the reported book.

Managers reporting it24of 720 we track
Value they reportUSD 168mshares only, 30 Jun 2026
Funds they run482with a file on PPLI.com
Largest positionUSD 79mTwo Sigma Investments
Typical weight0.0%median share of a manager's book
Heaviest weight3.0%Palo Alto Investors

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

24 managers, USD 168m between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Iovance Biotherapeutics, Inc., largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Two Sigma Investments35 funds on PPLI.comUSD 79m0.1%
2Millennium Management6 funds on PPLI.comUSD 35m0.0%
3Palo Alto Investors6 funds on PPLI.comUSD 22m3.0%
4D. E. Shaw & Co.15 funds on PPLI.comUSD 8.9m0.0%
5Citadel Advisors32 funds on PPLI.comUSD 8.8m0.0%
6Voloridge Investment Management6 funds on PPLI.comUSD 2.9m0.0%
7CM Management1 fund on PPLI.comUSD 1.9m1.2%
8Balyasny Asset Management25 funds on PPLI.comUSD 1.6m0.0%
9Corsair Capital Management1 fund on PPLI.comUSD 1.5m0.2%
10Squarepoint Ops7 funds on PPLI.comUSD 1.4m0.0%
11Tudor Investment Corporation10 funds on PPLI.comUSD 1.2m0.0%
12Exoduspoint Capital Management7 funds on PPLI.comUSD 1.1m0.0%
13Engineers Gate Manager1 fund on PPLI.comUSD 791,0000.0%
14Brevan Howard Capital Management39 funds on PPLI.comUSD 341,0000.0%
15Jain Global1 fund on PPLI.comUSD 340,0000.0%
16Scientech Research2 funds on PPLI.comUSD 274,0000.2%
17Freestone Grove Partners1 fund on PPLI.comUSD 178,0000.0%
18LMR Partners2 funds on PPLI.comUSD 171,0000.0%
19Marshall Wace LLP84 funds on PPLI.comUSD 164,0000.0%
20Schonfeld Strategic Advisors30 funds on PPLI.comUSD 62,0710.0%
21Magnetar Financial93 funds on PPLI.comUSD 55,9440.0%
22CIBC Asset Management69 funds on PPLI.comUSD 52,9980.0%
23The Quarry1 fund on PPLI.comUSD 2,6830.0%
24Walleye Capital8 funds on PPLI.comUSD 9030.0%
Next: where it matters most
Where it matters most

For Palo Alto Investors it is 3.0% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Palo Alto InvestorsUSD 22m3.0%
2CM ManagementUSD 1.9m1.2%
3Scientech ResearchUSD 274,0000.2%
4Corsair Capital ManagementUSD 1.5m0.2%
5Two Sigma InvestmentsUSD 79m0.1%
6Millennium ManagementUSD 35m0.0%
7Voloridge Investment ManagementUSD 2.9m0.0%
8Engineers Gate ManagerUSD 791,0000.0%
9Exoduspoint Capital ManagementUSD 1.1m0.0%
10D. E. Shaw & Co.USD 8.9m0.0%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Iovance Biotherapeutics, Inc.

What is the ticker symbol of Iovance Biotherapeutics, Inc.?

Iovance Biotherapeutics, Inc. trades under the symbol IOVA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 462260100.

Which hedge funds own Iovance Biotherapeutics, Inc. (Nasdaq: IOVA)?

24 of the 720 hedge fund managers PPLI.com tracks reported Iovance Biotherapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Two Sigma Investments (USD 79m), Millennium Management (USD 35m), Palo Alto Investors (USD 22m), D. E. Shaw & Co. (USD 8.9m) and Citadel Advisors (USD 8.8m).

How many hedge funds hold Iovance Biotherapeutics, Inc.?

24 managers in our coverage reported it, and between them they run 482 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Iovance Biotherapeutics, Inc.?

Palo Alto Investors, where the position was 3.0% of the reported 13F book at 30 June 2026.

Does this show who is short Iovance Biotherapeutics, Inc.?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Iovance Biotherapeutics, Inc. or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.